Fig. 5: MSA overcomes BCR/ABL-T315I-induced drug resistance.
From: GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells
a KBM5-T315I and 32D-T315I cells were treated with MSA for 48 h, and the cell viability was determined. b T315I cells were treated with MSA for 48 h under glucose deprivation and cell counting was conducted. Colony formation of KBM5-T315I and 32D-T315I cells with 0.075 mM MSA treatment was measured (c), and the number and diameter of CFUs were shown (d). e, f KBM5 and KBM5-T315I cells were treated with MSA for 48 h under glucose deprivation, and apoptosis was conducted by flow cytometry. T315I cells were treated with MSA, and GPXs enzyme activity (g), OCR (h) and ATP level (i) were determined. j T315I cells were treated with MSA for 48 h and subjected to Western blot. Data are expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
